The promise of natural killer (NK) cells as effectors in cancer cellular therapy is limited by their expression of dominant inhibitory receptors for human leukocyte antigen (HLA) class I. Here, we discuss how chimeric antigen receptors (CARs) engineered to override inhibitory signaling might boost NK cell antitumor responses, independently of blockade of NK cell inhibitory receptors.

中文翻译：

---

NK细胞癌症免疫疗法的抗抑制性CAR。

天然杀伤（NK）细胞在癌症细胞治疗中作为效应子的前景受到人类白细胞抗原（HLA）I类主要抑制受体表达的限制。在这里，我们讨论如何设计嵌合抗原受体（CARs）以覆盖抑制性信号传导可能会增强NK细胞的抗肿瘤反应，而与NK细胞抑制受体的阻滞无关。